CHAPTER V

CONCLUSION

In this research, *ent*-kaur-16-en-19-oic acid (1) was isolated from the stem bark of *C. oblongifolius* (Amphur Kuiburi, Prachuab Kirikhan Province) and *ent*-1,2dehydro-3-oxomanoyl oxide (2), *ent*-1 β -hydroxy-3-oxomanoyl oxide (3) and *ent*-1,2dehydro-12 α -hydroxy-3-oxomanoyl oxide (4) were isolated from the stem bark of *C. oblongifolius* (Loei Province).

Biotransformation of the kaurane diterpene (*ent*-kaur-16-en-19-oic acid, <u>1</u>) with Absidia blakesleeana, Rhizopus oligosporus and Aspergillus ficuum are shown in Table 5.1 and Scheme 5.1. Biotransformation of the labdane diterpene (*ent*-1,2-dehydro-3-oxomanoyl oxide, <u>2</u>) by Rhizopus oligosporus, Rhizopus stolonifer and Mucor plumbeus are shown in Table 5.2 and Scheme 5.2.



Scheme 5.1 The biotransformation of ent-kaur-16-en-19-oic acid.

Fungus	Metabolite	Weight (mg)	% yield from
			starting
			material
Absidia	1a , <i>ent</i> - $(7\alpha, 9\alpha)$ -dihydroxy-kaur-	33	6.8
blakesleeana	16-en-19-oic acid		
	1b, <i>ent</i> - $(7\alpha, 11\beta)$ -dihydroxy-	75	15.5
	kaur-16-en-19-oic acid		
	1c, ent- $(1\beta,7\alpha)$ -dihydroxy-kaur-	45	9.3
	16-en-19-oic acid	- 	
	1d, <i>ent</i> -(7α,13)-dihydroxy-kaur-	65	13.4
	16-en-19-oic acid		
Rhizopus	1e, ent-7α-hydroxy-kaur-16-en-	35	8.1
oligosporus	19-oic acid		
	1a , <i>ent</i> - $(7\alpha, 9\alpha)$ -dihydroxy-kaur-	45	10.4
	16-en-19-oic acid	a P	
	1f , <i>ent</i> - $(7\alpha, 16, 17)$ -trihydroxy-	23	5.3
	kaur-16-en-19-oic acid		
Aspergillus	1b , <i>ent</i> -(7α , 11 β)-dihydroxy-	102	28.3
ficuum	kaur-16-en-19-oic acid		

Table 5.1 The biotransformation of *ent*-kaur-16-en-19-oic acid.



Scheme 5.2 The biotransformation of *ent*-1,2-dehydro-3-oxomanoyl oxide.

54

.

Fungus	Metabolite	Weight (mg)	% yield from
			starting
			material
Rhizopus	2a , <i>ent</i> -11α-hydroxy-1,2-	230	46.0
oligosporus	dehydro-3-oxomanoyl oxide		
	2b , <i>ent</i> -(11α,14ξ,15)-trihydroxy-	8	1.6
	1,2-dehydro-3-oxomanoyl		
	oxide		
Rhizopus	2a , <i>ent</i> -11 α -hydroxy-1,2-	64	12.8
stolonifer	dehydro-3-oxomanoyl oxide		
	2c , <i>ent</i> -11 α -hydroxy-3-	40	8.0
	oxomanoyl oxide		
Mucor	2a , ent-11 α -hydroxy-1,2-	50	10.0
plumbeus	dehydro-3-oxomanoyl oxide		
	2b , <i>ent</i> -(11α,14ξ,15)-trihydroxy-	72	14.4
	1,2-dehydro-3-oxomanoyl		
	oxide		
	1	1	1

Table 5.2 The Biotransformation of ent-1,2-dehydro-3-oxomanoyl oxide.

The systematic use of different microorganisms may greatly facilitate the production of novel hydroxylated derivatives, which can then be tested for possible biological activity.

Suggestion for the future work

- 1. More work is needed to be done in order to understand the relationship between the *ent*-kaurane diterpenoids and the enzymes responsible for their hydroxylation, as well as to perform large-scale biotransformations with improved yields of desirable products.
- 2. Extension of this strategy to obtain rapid access to other diterpenoid derivatives should be investigated and a study of the potential biological activities of the biotransformed products should be carried out.